chevron_leftBack
As of 13 June 2026, Tenax Therapeutics, Inc. has a market cap of $304.51M USD, ranking #18498 globally and #3089 in the United States.
It ranks #1671 in the Healthcare sector, and #606 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$304.51MUSD
Enterprise Value
$656.08MUSD
Net Income (TTM)
-$52.6MUSD
PB Ratio
6.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher Giordano
open_in_new
Employees
16
Founded
1967
Website
tenaxthera.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -12% | -8.2% | -14% | -8.8% | 77% | 118% |
News
Loading...
TENX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TENX
Tenax Therapeutics Inc
ISIN: US88032L6056
Shares Out.:
Shares Outstanding:
26.525M1
Shares Float:
24.068M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
12.78 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
250K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
180K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
118K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
90K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
49K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
39K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
105K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
95K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
90K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
60K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
36K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
36K%
80.96B GBP
|
14.6
|
chevron_leftBack